(And that was in just 30 weeks.) In trials of Wegovy (which has a higher dose of semaglutide than Ozempic), patients who took it for two years lost an average of 15.2 percent of their body weight, while over a third dropped at least 20 percent, nearly double that of any other weight-loss medication on the market
Wright: [00:38:14] I got that one
Some allege semaglutide, the active ingredient in Ozempic, may be linked to risks, including blood clots in the legs
A growing number of evidence indicates that GLP-1-based therapies have anti-inflammatory effects in various cells, tissues, and organs by reducing the synthesis of pro-inflammatory cytokines and limiting immune cell infiltration
Weight loss drugs have shown some success Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years